Carglumic Acid Market

Carglumic Acid Market Size by Dosage Form (Orally Disintegrating Tablets, Dispersible Tablets and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2024 to 2033

Base Year: 2023 Historical Data: 2020-22
  • Report ID: TBI-14090
  • Published Date: Feb, 2024
  • Pages: 238
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

The global Carglumic Acid market generated USD 138.27 million revenue in 2023 and is projected to grow at a CAGR of 7.38% from 2024 to 2033. The market is expected to reach USD 281.81 million by 2033. The expansion of the carglumic acid market can be ascribed to various factors, among them the rising prevalence of numerous cancer diseases linked to lifestyle choices like excessive alcohol consumption, tobacco use, and sedentary behaviour. Moreover, the heightened awareness surrounding rare diseases and the expanding applications of carglumic acid are poised to stimulate the market's growth potential. Additionally, the increasing incidence rates of metabolic disorders such as hepatic encephalopathy, Reye's syndrome, and cirrhosis globally are anticipated to contribute significantly to the overall market demand.

Market Introduction:

Carglumic acid is a pharmaceutical compound that significantly reduces ammonia concentrations in the bloodstream. This medication is instrumental in addressing conditions associated with elevated ammonia levels, particularly in metabolic disorders. One of its primary applications is in treating hyperammonemia, where it plays a pivotal role in mitigating the harmful effects of excess ammonia. Carglumic acid is known for its efficacy in lowering ammonia levels, making it a crucial therapeutic option for individuals facing conditions such as propionic acidemia, methylmalonic academia, and N-acetylglutamate synthase (NAGS) deficiency. It functions by aiding in regulating ammonia metabolism, thereby assisting the body in maintaining a balance in ammonia levels. Notably, carglumic acid has received approval from the FDA for specific indications related to hyperammonemia due to NAGS deficiency, propionic acidemia, and methylmalonic academia. The compound's significance extends to its role as an adjunctive therapy, often administered alongside standard care practices. As a pharmaceutical agent, carglumic acid reflects the ongoing advancements in addressing rare and complex metabolic disorders. Its use underscores the continuous efforts within the pharmaceutical industry to develop targeted therapies that address specific biochemical imbalances, offering patients a more tailored and effective treatment approach.

Carglumic Acid Market Size

Get an overview of this study by requesting a free sample

Recent Development
  • In December 2021: Eton Pharmaceuticals, Inc., an innovative pharmaceutical firm specializing in the development and commercialization of treatments for rare diseases, and ANI Pharmaceuticals, Inc., a biopharmaceutical company committed to supplying top-quality generic and branded medicines, jointly announced the official launch of Carglumic Acid tablets. Eton Pharmaceuticals will lead the marketing efforts for this product, marking a significant milestone as it becomes the first and only FDA-approved generic version of Carbaglu. FDA approval for Carglumic Acid tablets was granted for treating acute and chronic hyperammonemia resulting from N-acetylglutamate synthase (NAGS) deficiency. Notably, the product holds an AB rating, demonstrating both bioequivalence and therapeutic equivalence to Carbaglu. This designation allows pharmacies to substitute Carglumic Acid tablets instead of Carbaglu prescriptions.

Market Dynamics:


Rising Incidence of Urea Cycle Disorders (UCD) - One of the primary drivers of the carglumic acid market is the increasing prevalence of urea cycle disorders. These genetic disorders lead to a deficiency in enzymes responsible for the urea cycle, accumulating ammonia in the bloodstream. Carglumic acid is an effective treatment for hyperammonemia associated with UCD.

Growing Awareness and Diagnosis of Rare Diseases - With increasing attention among healthcare professionals and the general population, there is a growing emphasis on diagnosing and treating rare diseases, including urea cycle disorders. This growing attention contributes to the demand for medications such as carglumic acid.

Advancements in Medical Research and Diagnostics - Ongoing advancements in medical research and diagnostic techniques are crucial in identifying and understanding rare genetic disorders. As the understanding of urea cycle disorders improves, the demand for targeted treatments like carglumic acid will likely increase.


Stringent Regulatory Processes - The regulatory processes for approving drugs, especially for rare diseases, can be rigorous. Delays in obtaining regulatory approvals can slow down the availability of carglumic acid in certain markets, impacting patient access.

Competition from Alternative Therapies - Carglumic acid faces competition from alternative therapies and treatment options for hyperammonemia and urea cycle disorders. The availability of other medications or interventions may limit the market share of carglumic acid.

Storage and Administration Challenges - Specific storage requirements and administration challenges associated with carglumic acid pose practical difficulties for healthcare providers and patients, potentially impacting its adoption.


Pediatric Formulation Development - Developing formulations specifically designed for pediatric use presents an opportunity for pharmaceutical companies. This factor is crucial as urea cycle disorders often manifest in childhood, and pediatric-friendly formulations could enhance treatment options.

Collaborations for Clinical Trials - Alliances between research institutions, pharmaceutical companies, and healthcare organizations can advance clinical trials, potentially leading to faster regulatory approvals and market entry for carglumic acid.

Orphan Drug Designation Incentives - The potential for orphan drug designation and associated incentives, such as extended market exclusivity and reduced regulatory fees, allows pharmaceutical companies to focus on developing and commercializing carglumic acid for rare diseases.


High Development Costs - The costs associated with the research, development, and clinical trials of medications for rare diseases can be exceptionally high. This financial burden may discourage investment in carglumic acid development.

Limited Patient Population - One of the primary challenges is the limited patient population with urea cycle disorders. The rarity of these genetic conditions makes it challenging for pharmaceutical companies to justify extensive research and development efforts for carglumic acid.

Regional segmentation analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the most prominent global Carglumic Acid market, with a 41.25% market revenue share in 2023.

North America has a relatively higher prevalence of urea cycle disorders than other regions. The occurrence of genetic conditions leading to hyperammonemia creates a substantial patient population in need of treatments like carglumic acid. Furthermore, the region boasts advanced healthcare infrastructure, including well-established medical facilities, research institutions, and specialized treatment centres. This infrastructure supports diagnosing and managing rare diseases, increasing the demand for carglumic acid. North America has a robust research and development landscape, with numerous pharmaceutical and biotechnology companies actively developing rare disease treatments. This factor fosters innovation and the exploration of new therapeutic options, including carglumic acid. Additionally, the regulatory standards for drug approval in North America are stringent, ensuring the safety and efficacy of pharmaceuticals. Carglumic acid, if meeting these standards, may benefit from expedited approvals and orphan drug designations, providing incentives for market entry. The United States, in particular, has one of the highest healthcare spending rates globally. This substantial investment in healthcare contributes to increased accessibility to advanced treatments, such as carglumic acid. In addition, there is a growing awareness of rare diseases, including urea cycle disorders, among healthcare professionals and the general population in North America. This increased awareness leads to more accurate and timely diagnoses, driving the demand for targeted treatments like carglumic acid.

North America Region Carglumic Acid Market Share in 2023 - 41.25%

Check the geographical analysis of this market by requesting a free sample

Dosage Form Segment Analysis

The dosage form segment is divided into orally disintegrating tablets, dispersible tablets and others. The dispersible tablets segment dominated the market, with a share of around 54.29% in 2023. Dispersible tablets are often designed to dissolve easily in water, making them more convenient for patients, especially those with difficulty swallowing traditional tablets or capsules. Improved ease of administration can enhance patient compliance with the prescribed treatment. Additionally, dispersible tablets are particularly useful in pediatric populations where swallowing solid dosage forms can be challenging. The ease of administration makes dispersible tablets a preferred choice for treating children with conditions like urea cycle disorders. Furthermore, dispersible tablets are formulated to dissolve rapidly in water, leading to quick medication absorption. This factor can be advantageous in cases where a fast-acting therapeutic effect is desirable, such as treating acute hyperammonemia.

Distribution Channel Segment Analysis

The distribution channel segment is classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market, with a share of around 60.13% in 2023. Carglumic acid is primarily used in the treatment of rare genetic disorders like urea cycle disorders. These disorders usually require specialized medical care and management, commonly provided in hospitals. In addition, patients with severe cases of urea cycle disorders, leading to acute hyperammonemia, may require inpatient treatment and monitoring. Hospital pharmacies are well-equipped to handle the dispensing and administration of medications in an inpatient setting. Carglumic acid may be used in emergencies where prompt intervention is necessary to manage hyperammonemia. Hospital pharmacies are essential in providing immediate access to medications needed in critical care scenarios.

Some of the Key Market Players:
  • Apothecon Pharmaceuticals Pvt. Ltd.
  • Biophore India Pharmaceuticals Pvt. Ltd.
  • Civentichem LLC
  • Dipharma
  • Eton Pharmaceuticals
  • Manus Aktteva Biopharma LLP
  • Recordati Rare Diseases Inc.
  • Nuray Chemicals
  • Novitium Pharma LLC
  • Rhyme Organics and Chemicals Ltd.
  • Suven Life Sciences Limited

Report Description:

Attribute Description
Market Size Revenue (USD Billion)
Market size value in 2023 USD 138.27 Million
Market size value in 2033 USD 281.81 Million
CAGR (2024 to 2033) 7.38%
Historical data 2020-2022
Base Year 2023
Forecast 2024-2033
Region The regions analyzed for the market are Asia Pacific, Europe, South America, North America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
Segments Dosage Form and Distribution Channel

Frequesntly Asked Questions

As per The Brainy Insights, the size of the carglumic acid market was valued at USD 138.27 million in 2023 to USD 281.81 million by 2033.

The global carglumic acid market is growing at a CAGR of 7.38% during the forecast period 2024-2033.

North America became the largest market for carglumic acid.

Rising incidence of urea cycle disorders (UCD) and growing awareness and diagnosis of rare diseases drive the market's growth.

Request Table of Content


This study forecasts revenue at global, regional, and country levels from 2020 to 2033. The Brainy Insights has segmented the global Carglumic Acid market based on below-mentioned segments:

Global Carglumic Acid Market by Dosage Form:

  • Orally Disintegrating Tablets   
  • Dispersible Tablets             
  • Others       

Global Carglumic Acid Market by Distribution Channel:

  • Hospital Pharmacies         
  • Retail Pharmacies
  • Online Pharmacies

Global Carglumic Acid Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa


Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:


Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights


Free Customization


Fortune 500 Clients


Free Yearly Update On Purchase Of Multi/Corporate License


Companies Served Till Date